Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Mar, 2017 | Pages:
147 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Candidiasis - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Candidiasis - Pipeline Review, H1 2017, provides an overview of the Candidiasis (Infectious Disease) pipeline landscape. Candidiasis is caused by infection with species of the genus Candida, predominantly with Candida albicans. A Candida infection of the skin appears as a clearly defined patch of red, itchy skin, often leaking fluid. Scabs and pustules may be seen around the edge of the rash. It will usually be found in areas such as the groin, the folds of the buttocks, between the breasts, toes, or fingers, and in the navel. Treatment includes anti fungal drugs. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Candidiasis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Candidiasis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Candidiasis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Candidiasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 8, 4, 20 and 10 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 10 and 9 molecules, respectively. Candidiasis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Candidiasis (Infectious Disease). - The pipeline guide reviews pipeline therapeutics for Candidiasis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Candidiasis (Infectious Disease) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Candidiasis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Candidiasis (Infectious Disease) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Candidiasis (Infectious Disease). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Candidiasis (Infectious Disease) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Candidiasis - Overview 8 Candidiasis - Therapeutics Development 9 Pipeline Overview 9 Pipeline by Companies 10 Pipeline by Universities/Institutes 13 Products under Development by Companies 15 Products under Development by Universities/Institutes 18 Candidiasis - Therapeutics Assessment 19 Assessment by Target 19 Assessment by Mechanism of Action 21 Assessment by Route of Administration 23 Assessment by Molecule Type 25 Candidiasis - Companies Involved in Therapeutics Development 27 Amplyx Pharmaceuticals Inc 27 Bakker Medical Srl 27 Biomar Microbial Technologies 28 Biosergen AS 28 Cidara Therapeutics Inc 29 CSA Biotechnologies LLC 29 Daewoong Pharmaceutical Co Ltd 30 Dermala Inc 30 General Biologicals Corp 31 Grupo Ferrer Internacional SA 31 Hsiri Therapeutics LLC 32 iCo Therapeutics Inc. 32 ImmunoClin Corp 33 Matinas BioPharma Holdings Inc 33 Nanomerics Ltd 34 NovaDigm Therapeutics Inc 34 Novartis AG 35 Onxeo SA 35 Scynexis Inc 36 Sealife PHARMA GMBH 36 Viamet Pharmaceuticals Inc 37 Visterra Inc 37 Wellstat Vaccines LLC 38 Candidiasis - Drug Profiles 39 (clotrimazole + diclofenac sodium) - Drug Profile 39 61894700 - Drug Profile 40 AC-17 - Drug Profile 41 amphotericin B - Drug Profile 42 amphotericin B - Drug Profile 44 amphotericin B - Drug Profile 48 Amphotericin B sodium - Drug Profile 49 Antibody to Target Ece1 for Candidiasis - Drug Profile 51 APX-001 - Drug Profile 52 APX-001A - Drug Profile 54 arasertaconazole - Drug Profile 55 B-4010 - Drug Profile 56 BL-5923 - Drug Profile 57 BSG-005 - Drug Profile 58 candidiasis vaccine - Drug Profile 59 CD-101 - Drug Profile 60 Cellullar Immunotherapy for Viral Infections and Fungal Infections - Drug Profile 64 CSA-13 - Drug Profile 65 Drug for Candidiasis - Drug Profile 67 DWP-06081 - Drug Profile 68 Forazoline A - Drug Profile 69 iCo-010 - Drug Profile 70 interleukin-22 - Drug Profile 71 JSM-11 - Drug Profile 72 KSL-W - Drug Profile 73 miconazole nitrate - Drug Profile 74 Monoclonal Antibodies for Candidiasis - Drug Profile 76 Monoclonal Antibody for Candidiasis - Drug Profile 77 Monoclonal Antibody for Candidiasis and Gram-Positive Bacterial Infections - Drug Profile 78 mutanobactin A - Drug Profile 79 NDV-3 - Drug Profile 80 NDV-3A - Drug Profile 82 NP-339 - Drug Profile 84 obliquumol - Drug Profile 85 Occidiofungin - Drug Profile 86 P-113Du - Drug Profile 87 P-113Tri - Drug Profile 88 PAC-113 - Drug Profile 89 Polymers for Clostridium difficile Infections and Candidiasis - Drug Profile 91 Prof-002 - Drug Profile 92 Recombinant Enzyme for Candidiasis - Drug Profile 93 Recombinant Peptides for Oropharyngeal Candidiasis - Drug Profile 94 SCY-078 - Drug Profile 95 SLP-0901 - Drug Profile 100 SLP-0904 - Drug Profile 101 Small Molecule for Bacterial Vaginosis and Candidiasis - Drug Profile 102 Small Molecule for Fungal Infections - Drug Profile 103 Small Molecules for Aspergillosis and Candidiasis - Drug Profile 104 Small Molecules for Candidiasis - Drug Profile 105 Small Molecules for Candidiasis - Drug Profile 106 Small Molecules for Candidiasis - Drug Profile 107 Small Molecules for Fungal Infections - Drug Profile 108 Small Molecules for Fungal Infections - Drug Profile 109 Small Molecules for Systemic Candidiasis - Drug Profile 110 Synthetic Peptide to Inhibit CBL-B for Candidiasis - Drug Profile 111 Synthetic Peptides for Candidiasis - Drug Profile 112 Synthetic Peptides for Infections Diseases and Oncology - Drug Profile 113 TOL-463 - Drug Profile 114 Vaccine to Target Ece1 for Candidiasis - Drug Profile 115 Vaccine to Target Glucosylceramide for Fungal Infections - Drug Profile 116 VIS-FNG - Drug Profile 117 VT-1129 - Drug Profile 118 VT-1161 - Drug Profile 120 Candidiasis - Dormant Projects 126 Candidiasis - Discontinued Products 129 Candidiasis - Product Development Milestones 130 Featured News & Press Releases 130 Appendix 141 Methodology 141 Coverage 141 Secondary Research 141 Primary Research 141 Expert Panel Validation 141 Contact Us 141 Disclaimer 142
List of Tables
Number of Products under Development for Candidiasis, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Candidiasis - Pipeline by Amplyx Pharmaceuticals Inc, H1 2017 Candidiasis - Pipeline by Bakker Medical Srl, H1 2017 Candidiasis - Pipeline by Biomar Microbial Technologies, H1 2017 Candidiasis - Pipeline by Biosergen AS, H1 2017 Candidiasis - Pipeline by Cidara Therapeutics Inc, H1 2017 Candidiasis - Pipeline by CSA Biotechnologies LLC, H1 2017 Candidiasis - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017 Candidiasis - Pipeline by Dermala Inc, H1 2017 Candidiasis - Pipeline by General Biologicals Corp, H1 2017 Candidiasis - Pipeline by Grupo Ferrer Internacional SA, H1 2017 Candidiasis - Pipeline by Hsiri Therapeutics LLC, H1 2017 Candidiasis - Pipeline by iCo Therapeutics Inc., H1 2017 Candidiasis - Pipeline by ImmunoClin Corp, H1 2017 Candidiasis - Pipeline by Matinas BioPharma Holdings Inc, H1 2017 Candidiasis - Pipeline by Nanomerics Ltd, H1 2017 Candidiasis - Pipeline by NovaDigm Therapeutics Inc, H1 2017 Candidiasis - Pipeline by Novartis AG, H1 2017 Candidiasis - Pipeline by Onxeo SA, H1 2017 Candidiasis - Pipeline by Scynexis Inc, H1 2017 Candidiasis - Pipeline by Sealife PHARMA GMBH, H1 2017 Candidiasis - Pipeline by Viamet Pharmaceuticals Inc, H1 2017 Candidiasis - Pipeline by Visterra Inc, H1 2017 Candidiasis - Pipeline by Wellstat Vaccines LLC, H1 2017 Candidiasis - Dormant Projects, H1 2017 Candidiasis - Dormant Projects, H1 2017 (Contd..1), H1 2017 Candidiasis - Dormant Projects, H1 2017 (Contd..2), H1 2017 Candidiasis - Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
